Cumberland Pharmaceuticals (CPIX) Gross Margin (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Gross Margin across 17 years of filings, most recently posting 78.82% for Q1 2026.

• In Q1 2026, Gross Margin fell 901.0% year-over-year to 78.82%; the TTM figure through Mar 2026 stood at 77.21% (down 713.0% YoY), while the FY2025 annual figure was 85.02%, up 242.0% from the prior year.
• Gross Margin came in at 78.82% for Q1 2026 at Cumberland Pharmaceuticals, down from 83.61% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 88.08% in Q3 2025 to a low of 428.21% in Q2 2025.
• Average Gross Margin over 5 years is 52.43%, with a median of 82.49% recorded in 2023.
• Year-over-year, Gross Margin soared 1269 bps in 2023 and sank 51083 bps in 2025.
• Over 5 years, Gross Margin stood at 70.95% in 2022, then gained by 18 bps to 83.64% in 2023, then decreased by 3 bps to 81.06% in 2024, then advanced by 3 bps to 83.61% in 2025, then dropped by 6 bps to 78.82% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 78.82% in Q1 2026, 83.61% in Q4 2025, and 88.08% in Q3 2025.